Efficacy analysis of fulvestrant 500 mg treatment for patients with hormone receptor-positive advanced breast cancer

SONG Guohong, DI Lijun, SHAO Bin, ZHANG Ruyan, RAN Ran, WANG Huan, LEI Wen, WAN Fengling, LI Huiping

Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing100142, China

Online:2016-11-30 Published:2017-01-22
Contact: LI Huiping E-mail: huipingli2012@hotmail.com

Abstract

SONG Guohong, DI Lijun, SHAO Bin, et al. Efficacy analysis of fulvestrant 500 mg treatment for patients with hormone receptor-positive advanced breast cancer[J]. China Oncology, 2016, 26(11): 957-960.

[1]	CONG Binbin, WANG Yongsheng. Treatment landscape and challenges of managing the hormone receptor-positive early breast cancer [J]. China Oncology, 2021, 31(8): 689-696.
[2]	ZHAO Yannan, GONG Chengcheng, HU Xichun, et al. A retrospective study of 500 mg fulvestrant in recurrent or metastatic breast cancer patients pretreated with the third generation of aromatase inhibitors [J]. China Oncology, 2016, 26(9): 777-783.
[3]	WANG Jiayu, XU Binghe. Advances of fulvestrant in treatment of advanced breast cancer in hormone receptor-positive postmenopausal women [J]. China Oncology, 2016, 26(5): 471-475.
[4]	LI Jian-ying, JI Cong-fei, CHEN Jia, TAN Qing-he. Clinical observation of capecitabine in the maintenance treatment of advanced breast cancer [J]. China Oncology, 2014, 24(5): 381-386.

Efficacy analysis of fulvestrant 500 mg treatment for patients with hormone receptor-positive advanced breast cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 4

Recommended Articles

Metrics

Comments